Press Release

Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference

March 6, 2023 at 8:00 AM EST

BOSTON--(BUSINESS WIRE)--Mar. 6, 2023-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 1:20pm ET.

A webcast of the presentation can be accessed at the following link: An archived replay of the presentation will be available in the investors section of for 30 days following the event.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website,, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria Contacts:

Investor relations:
Andrea Matthews

Elizabeth Higgins

Source: Astria Therapeutics, Inc.

purple ball background